Drug intelligence / Profile preview

PYC38

Development stage: Unknown
Lead developer: PYC Therapeutics
Modality: Peptides

Overview

**PYC38** is a proprietary Phylomer peptide developed by Phylogica Ltd., a peptide drug discovery company based in Perth, Australia. Phylomers are trademarked cyclic peptides derived from biodiverse natural sources, designed for high specificity and stability. PYC38 belongs to a family of anti-inflammatory Phylomer peptides, including lead candidates PYC35, PYC36, and PYC38, positioned as drug candidates for multiple diseases and conditions with unmet needs. The company secured a US patent for PYC38 and its derivatives, highlighting its neuroprotective potential among other therapeutic applications. Specific details on mechanism of action, primary indications, or clinical development status remain limited in available sources.[3][4][7]

Other names: PYC38 Phylomer peptidePYC-38 Phylomer peptidePYC 38 Phylomer peptide

Beyond the preview

Go deeper on PYC38.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PYC38.

Explore the full profile